

RESEARCH

Open Access



Integrated proteomic and metabolomic profiling of lymph after trauma-induced hypercoagulopathy and antithrombotic therapy

Yangkang Zheng^{1,2,3,4}, Pengyu Wang^{1,2,3}, Lin Cong^{1,2,3}, Qi Shi^{1,2,3}, Yongjian Zhao^{1,2,3*} and YongJun Wang^{1,2,3*}

Abstract

Background Routine coagulation tests are not widely accepted diagnostic criteria of trauma-induced hypercoagulopathy (TIH) due to insensitivity. Lymphatic vessels drain approximately 10% of the interstitial fluid into the lymphatic system and form lymph.

Subjective The purpose of this study was to identify the potential lymph biomarkers for TIH.

Methods Eighteen male Sprague-Dawley rats were randomly assigned to the sham (non-fractured rats with sham surgery and vehicle treatment), the VEH (fractured rats with vehicle treatment) and the CLO (fractured rats with clopidogrel treatment) group. Thoracic duct lymph was obtained to perform proteomics and untargeted metabolomics.

Results A total of 1207 proteins and 16,695 metabolites were identified. The top 5 GO terms of lymph proteomics indicated that oxidative stress and innate immunity were closely associated with TIH and antithrombotic therapy. The top 5 GO terms of lymph metabolomics showed that homocystine and lysophosphatidylcholine were the differential expressed metabolites (DEMs) between the sham and VEH groups, while cholic acid, docosahexaenoic acid, N1-Methyl-2-pyridone-5-carboxamide, isoleucine and testosterone are the DEMs between the VEH and CLO group.

Conclusions This study presents the first proteomic and metabolomic profiling of lymph after TIH and antithrombotic therapy, and predicts the possible lymph biomarkers for TIH.

Keywords Trauma-induced hypercoagulopathy, Thoracic duct lymph, Proteomics, Untargeted metabolomics, Antithrombotic therapy

*Correspondence:

Yongjian Zhao
zhaoyongjian521@126.com

YongJun Wang
wangyongjun@shutcm.edu.cn

¹Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 Wan-Ping South Road, Shanghai 200032, China

²Spine Institute, Shanghai University of Traditional Chinese Medicine, 725 Wan-Ping South Road, Shanghai 200032, China

³Key Laboratory of Theory and Therapy of Muscles and Bones, Ministry of Education, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, China

⁴Department of Biochemistry and Molecular Cell Biology, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Trauma-induced coagulopathy (TIC) is a dynamic and complex coagulation dysfunction, characterized by hypo-coagulability in the early hours, resulting in hemorrhagic shock, and hypercoagulability following the hypocoagulable state, resulting in venous thromboembolism and multiple organ failure [1]. As a result, TIC is regarded as an independent risk factor for poor prognosis among trauma patients [2–5]. Most studies on TIC mainly focus on hypocoagulability, however, 22.2–85.1% of trauma patients within days of injury develop trauma-induced hypercoagulopathy (TIH). TIH raises the risk of thrombotic events and mortality by 2–4 times [3, 6, 7]. Hence, discovering the potential biomarkers of TIH is essential for medical practice [4].

Routine coagulation tests, such as prothrombin time (PT), activated partial prothrombin time (APTT), D-dimers (DD) and fibrinogen (or fibrin) degradation products (FDPs), are suggested as the diagnostic indicators of TIH. However, these are not widely accepted diagnostic criteria of TIH due to the insensitivity [4]. Lymphatic vessels, as the second circulatory pathway, drain approximately 10% of the interstitial fluid into the lymphatic system and form lymph [8]. At the end of lymphatic draining pathways, most lymph is returned to the circulatory system through the thoracic duct. In contrast to blood vessels, lymphatic vessels play a vital role in macromolecule transport, lipid metabolism and waste clearance [9–13]. Previous research also demonstrates that lymph is not a plasma ultrafiltrate and presents some unique substances [14]. Therefore, to compensate for the shortcomings of serum and plasma, lymph might be a potential and valuable source of novel biomarkers for TIH.

Our previous investigation found that lymphatic drainage insufficiency was caused by a significant amount of lymphatic platelet thrombosis (LPT) blocking lymphatic vessels on the first day post-traumatic fracture [15]. By removing LPT, a low dose of clopidogrel rapidly restored lymphatic drainage function and alleviated early fracture complications [15]. These results suggest that traumatic fracture on the first day causes TIH, which is not only manifested with deep venous thrombosis, but also with LPT. Therefore, to explore the early constitutive alterations in lymph after TIH, we utilized integrated proteomic and metabolomic analysis of lymph in the sham group (non-fractured rats with sham surgery and vehicle treatment) and the vehicle (VEH) group (fractured rats with vehicle treatment). Furthermore, to find possible TIH biomarkers and unveil the lymphatic clearance mechanism treated with a blood thinner, we employed integrated proteomic and metabolomic analysis of lymph in the VEH group and clopidogrel (CLO) group (fractured rats with clopidogrel treatment).

Methods

Animals

This study was approved by Shanghai University of Traditional Chinese Medicine-Animal Ethics Committee (PZSHUTCM211101023). Eighteen 8~10-week-old Sprague-Dawley rats (Shanghai Jessie Experimental Animal Co., Ltd) were kept in isolation cages in the animal center with a 12-hour light/dark cycle. All rats were fed with regular rodent's chow and sterilized tap water *ad libitum*. Eighteen rats were randomly assigned to three groups ($N=6$ /group) and accommodated for 1 week before experimental procedures.

Thoracic duct lymph collection

Cannulation of the thoracic lymph duct was carried out as the previous study described [16]. Isoflurane inhalation (5% induction at a flow rate of 3 L/min, 2% maintenance at a flow rate of 1 L/min) was used to induce and sustain general anesthesia. First, to expose the thoracic duct, we made a midline abdominal incision approximately two-thirds of the length of the abdomen posterior to the xiphoid cartilage. Second, we isolated the thoracic duct from the abdominal aorta, ligated the proximal ends of the thoracic duct with two 4–0 silks, and cannulated the thoracic duct with a 15 cm length of polyethylene tubing primed with heparinized saline. A white lymph was seen flowing in the tubing. Third, to collect the thoracic duct lymph, we firmly fixed the polyethylene tubing at the distant ends of the thoracic duct with two 4–0 silk, passed the polyethylene tubing through the peritoneum and skin, and connected the polyethylene tubing to the anticoagulant tube. Following repeated peritoneal lavages, the peritoneum and skin were sutured closed. Topical anesthetic cream was applied to the rats' suture line. Anticoagulant vacutainers need to be replaced every 2 h. At last, collected lymph samples at 24 h post-surgery were centrifuged at 1000 g for 10 min at 4 °C to remove insoluble cell lysates and precipitation before being stored at -20°C.

Establishment of rat TIH model

Fracture is acknowledged as a high risk factor of TIH [17–19]. In this study, traumatic fractured rats were used to generate a TIH model. After successfully cannulating the rats' thoracic lymph ducts, eighteen animals were randomly assigned to the sham, VEH, and CLO groups ($N=6$ /group). For the traumatic fracture-induced TIH model, the intact tibia was placed at a midpoint of two supports (30 mm apart for rat experiments). A weight of 500 g was dropped from a height of 20 cm by a modified three-point bending device. For the sham model, 6 cannulated rats were fed routinely with no operations. To simulate a real traumatic condition before

hospitalization, painkillers and antibiotics were not administered to fractured rats on day 1 post-surgery.

Antithrombotic therapy

Clopidogrel (Cat. No. HY-15,283, MedChemExpress) was dissolved in a solvent (2.5mL dimethyl sulfoxide, 15mL polyethylene glycol, 2.5mL Tween-80, and 30mL double distilled water), and intramuscularly injected near the right popliteal lymph node at 0.1 mg/kg of body weight for 5 days (once per day). For the CLO group, clopidogrel was given at 4 h after tibial fracture under the ultrasound guide. Rats in the sham and VEH groups were given the same volume of solvent.

Sample detection for proteomics

Sample preparation procedures include abundant protein depletion by ProteoExtract® Albumin Removal Kit (Cat. No.122,640, Millipore) [20], protein digestion, and sample desalting according to Shanghai Luming Biological Technology Co., LTD's instructions.

Liquid chromatography-mass spectrometry

The Proteomic data analysis was performed by Shanghai OE Biotech Co., Ltd. (Shanghai, China). All analyses were performed by a Tims TOF Pro mass spectrometer (Thermo, Bruker) equipped with an EASY-nLC 1200 system (Thermo, USA). Samples were loaded by a C18 column (15 cm × 75 μm) on an EASY-nLCTM 1200 system (Thermo, USA). The flow rate was 300 nL/min and linear gradient was set as follows: 0~66 min, 3–27% B; 66~73 min, 27–46% B; 73~84 min, 46–100% B; 84–90 min, 100% B. Ion mobility is set from 0.6 to 1.6 Vs/cm² and the collision energy range from 20 to 59 eV. The MS/MS spectra were recorded from 100 to 1700 m/z.

Database search

MS/MS spectra were searched using MaxQuant 1.6.17.0 against the *Rattus norvegicus*-10,116 database. Search database specific parameters are set as follows: Fixed modifications: Carbamidomethyl (C); Variable modification: Oxidation (M) and Acetyl(Protein N-term); digestion: trypsin; Precursor Qvalue cutoff: 0.01; Protein Qvalue cutoff: 0.01; Missed cleavage: 2; Quantity MS-Level: MS2.

Statistical analyses

A total of 1207 proteins expressed were identified as belonging to the proteome of lymph in this study. The thresholds of fold change (>1.2 or <0.83) and *P*-value<0.05 were used to identify differentially expressed proteins (DEPs). Then we found 41 upregulated and 21 downregulated proteins in the VEH group compared with the sham group. In addition, we found 69 upregulated and 54 downregulated proteins in the CLO

group compared with the VEH group. Annotation of all identified proteins was performed using GO (<http://www.blast2go.com/b2ghome>; <http://geneontology.org/>) and KEGG pathway (<http://www.genome.jp/kegg/>). DEPs were further used for GO and KEGG enrichment analysis. Protein-protein interaction analysis was performed using the String (<https://string-db.org/>). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) via the iProX partner repository [21, 22] with the dataset identifier PXD047692.

Sample preparation for metabolomics

Lymph samples stored at -80 °C were thawed at room temperature. 80 μL of the sample was added to a 1.5 mL Eppendorf tube with 240 μL methanol/acetonitrile solution (2:1, vol/vol), containing L-2-chlorophenylalanine (2 ug/mL) dissolved in methanol as internal standard, and the tube was vortexed for 1 min. The whole samples were extracted by ultrasonic for 10 min in an ice-water bath, and stored at -40 °C for 30 min. The extract was centrifuged at 4 °C (13,000 rpm) for 10 min. 200 μL of supernatant in a glass vial was dried in a freeze-concentration centrifugal dryer. 300 μL mixture of methanol and water (1:4, vol/vol) were added to each sample, samples vortexed for 30 s, extracted by ultrasonic for 3 min in an ice-water bath, then placed at -40 °C for 2 h. Samples were centrifuged at 4 °C (13,000 rpm) for 10 min. The supernatants (150 μL) from each tube were collected using crystal syringes, filtered through 0.22 μm microfilters, and transferred to LC vials. The vials were stored at -80 °C until LC-MS analysis. QC samples were prepared by mixing aliquots of the all samples to form a pooled sample.

Metabolomic LC-MS/MS analysis

Metabolomic LC-MS/MS analysis was performed using ACQUITY UPLC I-Class system (Waters Corporation, Milford, USA) coupled with Q-Exactive plus quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). An ACQUITY UPLC HSS T3 column (1.8 μm, 2.1×100 mm) was employed in both positive and negative modes. The mass range was from m/z 100 to 1,200. The resolution was set at 70,000 for the full MS scans and 17,500 for HCD MS/MS scans. The Collision energy was set at 10, 20 and 40 eV. The mass spectrometer operated as follows: spray voltage, 3,800 V (+) and 3,200 V (-); sheath gas flow rate, 40 arbitrary units; auxiliary gas flow rate, 8 arbitrary units; capillary temperature, 320 °C; Probe Heater Temperature, 350 °C; S-lens RF level, 50. To provide a set of data with high repeatability, the QCs were injected at regular intervals throughout the experiments.

Metabolomic data processing and statistical analysis

The raw LC-MS data were processed by the software Progenesis QI V3.0 (Nonlinear, Dynamics, Newcastle, UK) for baseline filtering, peak identification, integral, retention time correction, peak alignment, and normalization. The extracted data were then further processed by removing any peaks with a missing value (ion intensity=0) in more than 50% in groups, by replacing the zero value with half of the minimum value, and by screening according to the qualitative results of the compound. Compounds with resulting scores below 36 (out of 60) points were also deemed to be inaccurate and removed. A data matrix was combined from the positive and negative ion data.

The matrix was imported in R to carry out Principle Component Analysis (PCA) to observe the overall distribution among the samples and the stability of the whole analysis process. Orthogonal Partial Least-Squares-Discriminant Analysis (OPLS-DA) and Partial Least-Squares-Discriminant Analysis (PLS-DA) were utilized to distinguish the metabolites that differ between groups. To prevent overfitting, 7-fold cross-validation and 200 Response Permutation Testing (RPT) were used to evaluate the quality of the model.

Variable Importance of Projection (VIP) values obtained from the OPLS-DA model were used to rank the overall contribution of each variable to group discrimination. A two-tailed Student's T-test was further used to verify whether the metabolites of difference between groups were significant. Differential metabolites were selected with VIP values greater than 1.0 and *p*-values less than 0.05. Differential metabolites were further used for KEGG pathway (<http://www.genome.jp/kegg/>) enrichment analysis. The metabolomic data have been deposited to the MetaboLights (<https://www.ebi.ac.uk/metabolights/>) with the dataset identifier MTBLS9145.

Multi-omics data integration of lymph

Pearson's correlation tests were used to detect the associations between the differentially expressed proteins (DEPs) and differentially expressed metabolites (DEMs). The top 20 of DEPs and DEMs are selected based on VIP ranking. Common enrichment pathways of DEPs and DEMs are further presented with a Bubble plot.

Data availability

The data that support the findings of this study are available from the authors upon reasonable request.

Results

Scheme of the methodology

To explore early constitutive changes in lymph and reveal the potential pharmacodynamic mechanism of anti-thrombotic therapy for tissue repair after TIH, a total of

18 Sprague Dawley rats were randomly assigned to three groups. The sham group has 6 non-fractured rats with sham surgery and vehicle treatment, the vehicle (VEH) group has 6 traumatic fractured rats with vehicle treatment, and the clopidogrel (CLO) group has 6 fractured rats with clopidogrel treatment. The thoracic duct lymph at 24 h post-surgery were collected for integrated proteomics by 4D-label free and untargeted metabolomics by liquid-chromatography coupled with tandem mass spectrometry (LC-MS/MS). This design was illustrated in Supplementary Fig. 1.

Overview of proteomic data of lymph

Lymph proteomics identified 9970 peptides and 1207 proteins in total, wherein 120 proteins are more than 100 kDa in molecular weight, namely macro-molecules (Supplementary Fig. 2A). Furthermore, a total of 678 credible proteins were identified based on bioinformatics analysis. To ensure the reliability of 4D-label free, we projected their proteomic profiles onto one dot plot by principal component analysis (PCA), and one hierarchical clustering dendrogram of sample Euclidean distance (Supplementary Fig. 2B-C). 18 samples could be well clustered to respectively correspond to the sham, VEH, and CLO groups (Supplementary Fig. 2C). Samples in CLO group were closely clustered and clearly distinguished from the VEH group (Supplementary Fig. 2B). These data present good repeatability within groups and significant differences among groups. 266 proteins out of 678 credible proteins showed significant differences. DEPs were analyzed based on log₂ fold change (FC) > 1.2 and adjusted *P* value < 0.05 by t-test. Compared to the sham group, 41 proteins were significantly increased while 21 proteins were significantly decreased in the VEH group (Supplementary Fig. 1D). It implies that lymphatic vessels transport traumatic fracture-induced proteins at the injured sites. Compared to the sham or VEH group, the number of significantly increased proteins was greater than the number of significantly decreased proteins in the CLO group (Supplementary Fig. 1D). This suggests that thrombolytic therapy improves lymphatic drainage function and transports more proteins expressed at fracture sites. Venn plot further analyzed the number of overlapped and unique differential proteins between two groups (Supplementary Fig. 2D). Venn plot showed that 62 (41 up-regulated and 21 down-regulated), 123 (69 up-regulated and 54 down-regulated), and 191 (137 up-regulated and 54 down-regulated) proteins were significantly changed in the lymph among the VEH group vs. the sham group, the CLO group vs. the VEH group and the CLO group vs. the sham group, respectively (Supplementary Fig. 2D).

Proteomic analysis of lymph between the sham and VEH groups

62 DEPs were identified between the sham and VEH groups and presented in the hierarchical clustering heatmap (Fig. 1A). More details of these DEPs were shown in Supplemental Table 1. We further applied GO enrichment analysis of DEPs. The enriched GO terms were included by ListHits>1 and ranked by their corresponding $-\log_{10} P$ value. The top 5 GO terms of biological process (BP) enriched by up-regulated DEPs were maternal process involved in female pregnancy, response to oxidative stress, response to xenobiotic stimulus, aging, and negative regulation of protein export from nucleus. (Fig. 1B). While the top 5 GO terms of BP enriched by down-regulated DEPs were sorbitol metabolic process, sorbitol catabolic process, L-cysteine catabolic process to hypotaurine, L-cysteine catabolic process to taurine, and purine nucleotide salvage (Fig. 1C). These results imply that TIH mainly induces multiple harmful proteins expression and oxidative stress.

Proteomic analysis of lymph between the VEH and CLO groups

Our previous study found that a large amount of aggregated platelets forms thrombosis within lymphatic vessels and impeded lymphatic drainage function [15]. A low dose of clopidogrel resolved lymphatic platelet thrombosis (LPT) and alleviated the early complications of bone fracture via lymphatic transporting damage-associated molecular patterns (DAMPs) [15]. To reveal the pharmacodynamic mechanism and identify the potential protein markers of antithrombotic therapy for TIH, we identified 123 DEPs between VEH and CLO groups by hierarchical clustering heatmap (Fig. 2A). More details of DEPs were shown in Supplemental Table 1. We further applied GO enrichment analysis of DEPs. The enriched GO terms were included by ListHits>1 and ranked by their corresponding $-\log_{10} P$ value. The top 5 GO terms of BP enriched by up-regulated DEPs were proteasomal protein catabolic process, negative regulation of endopeptidase activity, proteolysis involved in cellular protein catabolic process, inosine catabolic process, and deoxyinosine catabolic process (Fig. 2B). While the top 5 GO terms of BP enriched by down-regulated DEPs were defense response to Gram-positive bacterium, innate immune response, complement activation, classical pathway, cytolysis, and complement activation (Fig. 2C). These results suggest antithrombotic therapy systematically alleviate excessive inflammatory and immune responses after TIH.

Overview of metabolomic data of lymph

A total of 16,695 metabolites were identified and they were primarily composed of carboxylic acids, fatty acyls, and derivatives (Supplementary Fig. 3B). To ensure the

reliability of untargeted metabolomic data of lymph, we analyzed metabolomic data of lymph with metabolites intensity distribution of quality control (QC) principal component analysis (PCA), orthogonal partial least squares analysis (OPLS-DA), and permutation analysis. The metabolites intensity distribution of quality QC samples showed the median line of the QC sample was approximately at the same level, indicating good stability and reproducibility of this experiment (Supplementary Fig. 3A). PCA plot showed that QC samples were closely clustered together, demonstrating the good stability of LC-MS (Supplementary Fig. 3C). Given the significant differences within the group, we further utilized OPLS-DA and permutation analysis to compare the difference between the sham & VEH groups, and the VEH&CLO groups. The results indicate a significant separation between the VEH group and sham group, and likewise between the VEH group and CLO group (Supplementary Fig. 3D-E). In addition, the results of permutation tests showed no over-fitting of the LC-MS data and suggest that the OPLS-DA model is valid (Supplementary Fig. 3E). To sum up, the lymph of the VEH group is different from the sham and CLO groups, respectively. The DEMs were analyzed based on P -value<0.05 by t-test and of variable important in projection (VIP)>1. 80 DEMs (46 up-regulated and 34 down-regulated), 116 DEMs (37 up-regulated and 79 down-regulated), and 210 DEMs (75 up-regulated and 135 down-regulated) were identified in the lymph among the VEH group vs. the sham group, the CLO vs. the VEH group, and the CLO group vs. the sham group, respectively (Supplementary Fig. 3F). Venn plot analyzed the number of overlapped and unique DEMs between two groups (Supplementary Fig. 3G).

Metabolomic analysis of lymph between the sham and VEH groups

We identified 80 DEMs between the sham and VEH groups. The hierarchical clustering heatmap further revealed the top 50 DEMs by VIP ranking (Fig. 3A). More details of DEMs were shown in Supplemental Table 2. We further conducted a KEGG pathway enrichment analysis of DEMs with a P -value less than 0.05. The pathway term enriched by up-regulated DEM was cysteine and methionine metabolism (Fig. 3B). The DEM was L-Homocystine. While the pathway terms enriched by down-regulated DEMs were choline metabolism in cancer and glycerophospholipid metabolism (Fig. 3C). These two pathways share the same DEMs, namely LysoPC (14:0/0:0), LysoPC (15:0/0:0), and LysoPC (17:0/0:0). This data depicts the metabolic profiling of lymph of rats with TIH.




Fig. 1 Proteomic analysis of lymph between the sham and VEH groups. **(A)** Hierarchical clustering heatmap of identified DEPs between the VEH group vs. the Sham group. Columns represent groups and rows represent proteins. Blue to red colors represent the expression level of protein from low to high. **(B)** Top 5 GO terms of biological process (BP), cellular component (CC), and molecular function (MF) enriched by the up-regulated proteins. **(C)** Top 5 GO terms of BP, CC, and MF enriched by the down-regulated proteins




Fig. 2 Proteomic analysis of lymph between the VEH and CLO groups. **(A)** Hierarchical clustering heatmap of identified DEPs between the CLO group vs. the VEH group. Columns represent groups and rows represent proteins. Blue to red colors represent the expression level of protein from low to high. **(B)** Top 5 GO terms of BP, CC, and MF enriched by the up-regulated proteins. **(C)** Top 5 GO terms of BP, CC, and MF enriched by the down-regulated proteins




Fig. 3 Metabolomic analysis of lymph between the sham and VEH groups. **(A)** Hierarchical clustering heatmap of identified metabolites. Columns represent groups and rows represent proteins. Blue to red colors represent the expression level of protein from low to high. **(B)** Bubble plot of the significant enrichment pathways of up-regulated metabolites. **(C)** Bubble plot of the significant enrichment pathways of down-regulated metabolites. Rich Factor is defined as the number of differential metabolites annotated to the pathways divided by all identified metabolites annotated to the pathway

Metabolomic analysis of lymph between the VEH and CLO groups

We identified 116 DEMs between the VEH and CLO groups. More details of DEMs were shown in Supplemental Table 2. We further conducted KEGG pathway enrichment analysis of DEMs with *P*-value less than 0.05. The hierarchical clustering heatmap revealed the top 50 DEMs by VIP ranking (Fig. 4A). The pathway terms enriched by up-regulated DEMs were bile secretion, primary bile acid biosynthesis, choline metabolism in cancer, and glycerophospholipid metabolism (Fig. 4B). The DEM of bile secretion and primary bile acid biosynthesis was cholic acid. The DEM of choline metabolism in cancer and glycerophospholipid metabolism was LysoPC (18:3/0:0). While the pathway terms enriched by down-regulated DEMs were biosynthesis of unsaturated fatty acids, prostate cancer, endocrine resistance, GnRH secretion, ovarian steroidogenesis, valine, leucine and isoleucine biosynthesis, pathways in cancer, valine, leucine and isoleucine degradation, aminoacyl-tRNA biosynthesis, nicotinate and nicotinamide metabolism and steroid hormone biosynthesis (Fig. 4C). Their DEMs were L-isoleucine, docosahexaenoic acid, dihomo- α -linolenic acid, testosterone, and N1-Methyl-2-pyridone-5-carboxamide. These results provide the potential pharmacodynamic mechanism and metabolic markers of antithrombotic therapy for TIH.

Integrated proteomic and metabolomic analysis of lymph

Proteins and metabolites in life have close interaction and mutual regulatory relationship. To provide more comprehensive biological information, we constructed an integrated proteomic and metabolomic analysis of lymph for TIH. Based on the VIP ranking of DEPs and DEMs, we included the top 20 DEPs and DEMs to analyze the correlation between the sham and VEH groups by Pearson correlation algorithm (Fig. 5A). Then we respectively perform KEGG pathway enrichment of the total DEPs and DEMs between the sham and VEH groups. Venn plot indicated that 73 KEGG pathways were enriched by the total DEPs and 5 KEGG pathways were enriched by total DEMs (Fig. 5B). Furthermore, bubble plot showed that the common enrichment pathway of DEPs and DEMs between the VEH group and sham group is folate biosynthesis (Fig. 5C). Likewise, Pearson's correlation analysis of the top 20 DEPs and DEMs between the VEH and CLO groups were shown (Fig. 6A). Venn plot indicated that 160 KEGG pathways were enriched by the total DEPs and 15 KEGG pathways were enriched by the total DEMs (Fig. 6B). Furthermore, the bubble plot showed that the common enrichment pathway of DEPs and DEMs between the VEH group and CLO group are prostate cancer, endocrine resistance, pathways in cancer, and nicotinate and nicotinamide metabolism (Fig. 6C).

Discussion


Multi-omic analysis of lymph for TIH is rare, perhaps due to the following two reasons. (1) Thoracic duct cannulation is more complex and invasive than blood sampling [23]. Anesthesiologists and critical care specialists frequently use this medical technique to treat severely ill patients. (2) TIH received little attention from researchers and physicians since they were primarily concerned with the early stages of TIC, such as trauma-induced hypocoagulability and hemorrhagic shock [5]. Our previous research shows that a low dose of clopidogrel reduces LPT and promotes bone repair via unblocking lymphatic transport of damage-associated molecular patterns (DAMPs); additionally, unblocked lymphatic vessels exclusively transport high-weight molecular DAMPs compared to the venous system [15]. This suggests that lymph is a promising and appealing source of biofluids for disease prediction, diagnosis, and treatment. We added a larger sample size of rats with TIH and collected their lymph to be sent for multi-omic analysis. We offer the first lymph profiling of protein and metabolite alterations, predict potential lymph biomarkers for TIH and antithrombotic therapy, and explain the possible pharmacodynamic mechanism of antithrombotic therapy for tissue healing.

Insight of lymph proteome


The lymph proteome highlights oxidative stress and innate immunity play important roles in TIH. Given the presence of overlapping DEPs in the top 5 Go terms of BP, we will focus on the link between the key DEPs and TIH in the discussion.

Monika et al. analyzed mesenteric lymph and plasma from traumatized or severely ill individuals using LC/MC [14]. Approximately 155 proteins were identified as uniquely existing in the lymph, including extracellular matrix-related proteins, actin cytoskeleton reorganization markers, and pancreatic proteins [14]. In our study, O88767 (Parkinson disease protein 7 homolog, Park7), P05197 (Elongation factor 2, Eef2), P07824 (Arginase-1, Arg1), P11232 (Thioredoxin, Txn), P30152 (Neutrophil gelatinase-associated lipocalin, Lcn2), P31044 (Phosphatidylethanolamine-binding protein 1, Pebp1), Q01129 (Decorin, Dcn), Q63716 (Peroxiredoxin-1, Prdx1), P07943 (Aldo-keto reductase family 1 member B1, Akr1b1) are the up-regulated proteins enriched in top 5 GO terms of BP (Fig. 1B). Monika's proteomic data [14] suggests that wounded patients' lymph, rather than plasma, may include Park7, Pebp1, and Prdx1. PARK7 is abundantly expressed in the brain, skeletal muscle, and adrenal gland (BioProject: PRJNA280600) and regulates mitochondrial dysfunction and oxidative stress [24, 25]. PEBP1, a tiny scaffold protein, inhibits protein kinase cascades and promotes ferroptosis cell death by binding

A



B



C






Fig. 4 Metabolomic analysis of lymph between the VEH and CLO groups. **(A)** Hierarchical clustering heatmap of identified metabolites. Columns represent groups and rows represent proteins. Blue to red colors represent the expression level of protein from low to high. **(B)** Bubble plot of the significant enrichment pathways of up-regulated metabolites. **(C)** Bubble plot of the significant enrichment pathways of down-regulated metabolites. Rich Factor is defined as the number of differential metabolites annotated to the pathways divided by all identified metabolites annotated to the pathway

A



B



C






Fig. 5 Integrated analysis of lymph between the sham and VEH groups. **(A)** Pearson's correlation analysis of the top 20 differential proteins and metabolites based on VIP ranking between the sham and VEH groups. **(B)** Venn plot on the number of co-pathways between the sham and VEH groups enriched by the total DEPs and DEMs. **(C)** Bubble plot of the co-pathways between the VEH group and the sham group enriched by the total DEPs and DEMs. * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$

A



B



C




Fig. 6 Integrated analysis of lymph between the VEH and CLO groups. **(A)** Pearson's correlation analysis of the top 20 differential proteins and metabolites based on VIP ranking between the VEH and CLO groups. **(B)** Venn plot on the number of co-pathways between the VEH and CLO groups enriched by the total DEPs and DEMs. **(C)** Bubble plot of the co-pathways between the VEH and CLO groups enriched by the total DEPs and DEMs. * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$

with 15-lipoxygenases (15-LO) to produce hydroperoxy-PE [26]. Prdx1 is an enzyme with several functions, including oxidative defense, aging, inflammation, redox signaling, cell cycle, and carcinogenesis [27]. This finding revealed that Park7, Pebp1, and Prdx1 in collected lymph were possible diagnostic markers of injured individuals.

TIH is caused by a complex interaction of numerous processes, involving vascular endothelial injury, platelet hyperactivity, excessive release of procoagulants, hyperfibrinogenemia, anticoagulant pathways impairment, and fibrinolysis shutdown [4]. Immunoregulatory platelet dysfunction is the main pathological mechanism of TIH, despite the platelet count is at a normal level [1, 28]. On the one hand, injury-induced platelet activation promotes platelets to bind with leukocytes, forms platelet-leukocyte aggregates and activates innate immune response [29, 30]. On the other hand, activated neutrophils and macrophages release extracellular traps to simulate platelet aggregation and thrombin formation [1]. Therefore, we assumed that thrombolysis therapy reduced not just TIH but also excessive immune response. Figure 2C shows that the lymph of the CLO group had much lower levels of pro-inflammatory and immune-associated proteins, as confirmed by the top 5 GO terms of BP. Except for Q5WRG2 (Angiogenin, Ang) and Q6P6T1 (Complement C1s subcomponent, C1s) were previously reported to be presented in both plasma and lymph after trauma [14], we discovered following new protein molecules of lymph, including P50115 (Protein S100-A8, S100a8), P52925 (High mobility group protein B2, Hmgb2), F7FP65 (Retinoic acid receptor responder protein 2, Rarres2), D3ZWD6 (Complement C8 alpha chain, C8a), P01836 (Ig kappa chain C region, A allele), P00697 (Lysozyme C-1, Lyz1), G3V9C7 (Histone H2B, Hist1h2bk), M0R485 (Peptidoglycan recognition protein 2, Pglyrp2), P55314 (Complement component C8 beta chain, C8b), Q91YB6 (Complement inhibitory factor H, Cfh), D3ZPI8 (Complement C8 gamma chain, C8g). Although these down-regulated proteins are linked to inflammatory and immunological responses, it's unclear if they're just found in lymph fluid. Hence, more study is needed to identify particular lymph biomarkers following TIH or TIH plus thrombotic treatment.

Insight of lymph metabolome

The metabolomic researches of trauma-induced hemorrhagic shock are continuously reported [31–35], while the metabolomic changes of TIH are still little known. We depicted the lymph metabolomics of TIH and the potential pharmaceutical effect of antithrombotic therapy.

Compared to the sham group, homocystine, the up-regulated metabolite in the lymph of the VEH group, is enriched in cysteine and methionine metabolism (Fig. 3B). Homocystine is synthesized via

transmethylation of methionine and enzymatic reaction [36]. Homocystine is regarded as an independent risk factor for thrombotic disorders and cardiovascular disease [37–39]. In addition, cysteine and methionine metabolism is also significantly increased in the plasma metabolome of injured animals and patients [31–35]. This result indicates that homocystine of lymph and plasma might be a potential biomarker of TIH.

Lysophosphatidylcholine is the main active component of oxidized low-density lipoprotein and can expand inflammation and exacerbate diseases by inducing the migration of lymphocytes and macrophages to produce pro-inflammatory cytokines [40–43]. Koji et al. detected lysophosphatidylcholine significantly increased in the mesenteric lymph on the model of trauma-induced hemorrhagic shock [43]. To our surprise, compared to the sham group, lysophosphatidylcholine is the down-regulated metabolite in the lymph of the VEH group and enriched in choline metabolism in cancer and glycerophospholipid metabolism (Fig. 3C). This result is opposite to that of previous research probably due to different animal models. Additionally, compared to the VEH group, lysophosphatidylcholine was found to significantly increase in the lymph of the CLO group (Fig. 4B). We inferred that (1) the sham, VEH, and CLO groups induced lysophosphatidylcholine generation due to operation; (2) In VEH group, lysophosphatidylcholine was accumulated in the injured sites and failed to be transported into thoracic duct due to the blockage of lymphatic vessels by lymphatic platelet thrombosis; (3) In CLO group, unblocked lymphatic vessels drained increased lysophosphatidylcholine of injured sites into thoracic duct.

Cholic acid is the main component of bile acids in the human body and has versatile roles in maintaining bile acid homeostasis, alleviating metabolic inflammation, and protecting neural injury [44]. Compared to the VEH group, cholic acid, enriched in bile secretion and primary bile acid biosynthesis, is significantly up-regulated in the CLO group. This result suggests that lymphatic platelet thrombolysis not only alleviates TIH but also improves systematic pathology.

Docosahexaenoic acid is an acknowledged neuroprotective and anti-inflammatory agent with multiple functions of alleviating endoplasmic reticulum and oxidative stress and regulating autophagy [45–48]. N1-Methyl-2-pyridone-5-carboxamide is one of the major metabolites of nicotinamide and is elevated in renal failure, vascular inflammation, chronic ulcerative colitis, and asthma [49–52]. Compared to the VEH group, docosahexaenoic acid, and N1-Methyl-2-pyridone-5-carboxamide are decreased in the CLO group (Fig. 4C). This is probably because antithrombotic therapy improves lymphatic transport of docosahexaenoic acid and

N1-Methyl-2-pyridone-5-carboxamide, thus inhibiting their accumulation at fracture sides and decreasing oxidative response and nicotinamide metabolism.

Isoleucine is a kind of branched chain and an essential amino acid for humans and animals [53]. Isoleucine plays diverse roles in physiological functions and metabolic pathways, including maintaining the growth and development of animals, enhancing immunity, regulating glucose transportation, and stimulating protein synthesis [53–56]. Testosterone is synthesized and secreted by testicular Leydig cells and the adrenal cortex and is regulated by the hypothalamic-pituitary-gonadal axis [57]. Testosterone plays irreplaceable roles in the growth and development of the human body, maintaining musculoskeletal homeostasis and regulating post-traumatic stress disorder [58–60]. Although little literature reports their direct relationships with trauma, the information above seems to imply that higher levels of isoleucine and testosterone are beneficial for patients with trauma. However, the data of lymph metabolomics indicated that the levels of isoleucine and testosterone in the CLO group were significantly lower than VEH group. Therefore, general analysis suggests that (1) thrombolysis therapy is good for relieving TIH, circulatory system disorder, and inflammatory and oxidative response; (2) but might lead to side effects, such as metabolic and endocrine disorders. In a word, these DEMs above are potential and sensitive biomarkers of TIH patients with antithrombotic therapy.

Limitations and outlook

TIH is a dynamic, sequential pathophysiological process. Our work focused on a single time point of TIH to evaluate the constitutive alterations of lymph using integrated proteome and metabolome. (2) To distinguish the different and unique biomarkers between blood-derived and lymph-derived samples, a time course co-analysis of plasma and lymph multi-omics in trauma patients is mandatory. (3) Because obtaining lymph is challenging, the previous collection of lymph in trauma patients is under the help of anesthesiologists and intensive care physicians. Multidisciplinary collaboration in clinical trials of trauma patients is required to investigate the relationship between the possible biomarkers and the prognosis of TIH in order to validate the sensitivity and specificity of screening lymph biomarkers in this study. (4) Given that men have a higher risk of traumatic fractures and TIH [61–64], we only employed young male rats in this experiment. To increase the study's relevance and effect, both genders are suggested to be incorporated into the study design.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12959-024-00634-3>.

Supplementary Material 1

Supplementary Material 2. Supplemental Fig. 1 Scheme of the methodology. 18 male Sprague Dawley rats were randomly assigned to three groups, respectively sham group (6 non-fractured rats with sham surgery and vehicle-treated), vehicle group (6 fractured rats with vehicle-treated), and clopidogrel group (6 fractured rats with clopidogrel-treated). Thoracic lymph on 24 h post-surgery was collected and centrifuged, the supernatant of lymph was detected by integrated proteomics and metabolomics to comprehensively describe the lymph profile of TIH. DEPs: differentially expressed proteins, DEMs: differentially expressed metabolites.

Supplementary Material 3. Supplemental Fig. 2 Overview of proteomic data of lymph. (A) The number of proteins corresponding to different molecular weight distributions. (B) PCA of identified proteins in Sham, VEH, and CLO groups. (C) Hierarchical clustering dendrogram of sample Euclidean distance in Sham, VEH, and CLO groups. (D) The number of up-regulated and down-regulated DEPs in different groups. (E) Venn plot of the DEPs of lymph in different groups.

Supplementary Material 4. Supplemental Fig. 3 Overview of metabolomic data of lymph. (A) Metabolites intensity distribution of QC samples. (B) The proportion of the identified metabolites in each chemical classification. (C) PCA plot of all samples of lymph. (D) OPLS-DA analysis of lymph. (E) Permutation analysis of lymph. To validate OPLS-DA mode, a cross-validation plot was analyzed by UPLC-Q-TOF/MS-based metabolomic data with 7-fold cross-validation and 200 times response permutation testing. (F) The number of up-regulated and down-regulated DEMs in different groups. (G) Venn plot of the DEMs of lymph in different groups.

Supplementary Material 5. Supplementary Table 1 Differentially expressed proteins identified in rat lymph.

Supplementary Material 6. Supplementary Table 2 Differentially expressed metabolites identified in rat lymph.

Acknowledgements

We thank to Professor Lianping Xing, from University of Rochester Medical Center, for guidance on lymphatic biology, and Professor Junling Liu, from Shanghai Jiao Tong University School of Medicine, for platelet biology. We thank the Shanghai Luming Biological Technology Co., LTD (Shanghai, China) for providing integrated proteomic and metabolomic services.

Author contributions

YJW, YKZ conceived and designed the study; YKZ, PYW, LC performed the experiments and analyzed the data; YKZ drafted the manuscript; YJW, YJZ, QS revised the manuscript. All authors have approved the final version of the manuscript and have agreed to be accountable for all aspects of the work.

Funding

This work was sponsored by research grants from National Natural Science Foundation (82174407 to YJZ), The Inheritance and Innovation Team Project of National Traditional Chinese Medicine (ZYXCXTD-C-202202 to WYJ), State Administration of Traditional Chinese Medicine Qi Huang Scholar to WYJ and Shanghai Top Priority Research Center construction project (No. 2022ZZ01009 for Yong-jun Wang).

Data availability

1. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) via the iProX partner repository with the dataset identifier PXD047692.2. The metabolomic data have been deposited to the MetaboLights (<https://www.ebi.ac.uk/metabolights/>) with the dataset identifier MTBS9145.

Declarations

Competing interests

The authors declare no competing interests.

Conflict of interest

The authors have no financial or commercial conflicts of interest for this study.

Received: 1 May 2024 / Accepted: 3 July 2024

Published online: 10 July 2024

References

- Moore EE, Moore HB, Kornblith LZ, Neal MD, Hoffman M, Mutch NJ, Schöchl H, Hunt BJ, Sauaia A. Trauma-induced coagulopathy. *Nat Rev Dis Primers*. 2021;7(1):30.
- Xu SX, Wang L, Zhou GJ, Zhang M, Gan JX. Risk factors and clinical significance of trauma-induced coagulopathy in ICU patients with severe trauma. *Eur J Emerg Med*. 2013;20(4):286–90.
- Moore HB, Moore EE, Liras IN, et al. Targeting resuscitation to normalization of coagulating status: Hyper and hypocoagulability after severe injury are both associated with increased mortality[J]. *Am J Surg*. 2017;214(6):1041–5.
- Song JC, Yang LK, Zhao W, Zhu F, Wang G, Chen YP, Li WQ. Chinese People's Liberation Army Professional Committee of Critical Care Medicine and Chinese Society of Thrombosis. Hemostasis and Critical Care, Chinese Medicine Education Association. Chinese expert consensus on diagnosis and treatment of trauma-induced hypercoagulopathy. *Mil Med Res*. 2021;8(1):25.
- Spahn DR, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt BJ, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. *Crit Care*. 2019;23(1):98.
- Branco BC, Inaba K, Ives C, et al. Thromboelastogram evaluation of the impact of hypercoagulability in trauma patients[J]. *Shock*. 2014;41(3):200–7.
- Brill JB, Badiee J, Zander AL, et al. The rate of deep vein thrombosis doubles in trauma patients with hypercoagulable thromboelastography[J]. *J Trauma Acute Care Surg*. 2017;83(3):413–9.
- Olszewski WL. The lymphatic system in body homeostasis: physiological conditions. *Lymphat Res Biol*. 2003;1(1):11–21. discussion 21–4.
- Petrova TV, Koh GY. Biological functions of lymphatic vessels. *Science*. 2020;369(6500):eaax4063.
- Petrova TV, Koh GY. Organ-specific lymphatic vasculature: from development to pathophysiology. *J Exp Med*. 2018;215(1):35–49.
- Oliver G, Kipnis J, Randolph GJ, Harvey NL. The lymphatic vasculature in the 21st Century: Novel Functional roles in Homeostasis and Disease. *Cell*. 2020;182(2):270–96.
- Alitalo K. The lymphatic vasculature in disease. *Nat Med*. 2011;17(11):1371–80.
- Wang Y, Oliver G. Current views on the function of the lymphatic vasculature in health and disease. *Genes Dev*. 2010;24(19):2115–26.
- Dzietkowska M, D'Alessandro A, Moore EE, Wohlauer M, Banerjee A, Silliman CC, Hansen KC. Lymph is not a plasma ultrafiltrate: a proteomic analysis of injured patients. *Shock*. 2014;42(6):485–98.
- Wang YJ, Zheng Y, Cong L, Wang P, Zhao L, Xing L, Liu J, Xu H, Li N, Zhao Y, Shi Q, Liang Q. Lymphatic platelet thrombosis limits bone repair by precluding lymphatic transporting DAMPs. *Res Sq [Preprint]*. 2023 Nov 14;rs.3.rs-3474507.
- Boyd M, Risovic V, Jull P, Choo E, Wasan KM. A stepwise surgical procedure to investigate the lymphatic transport of lipid-based oral drug formulations: Cannulation of the mesenteric and thoracic lymph ducts within the rat. *J Pharmacol Toxicol Methods*. 2004 Mar-Apr;49(2):115–20.
- Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. *Lancet*. 2016;388(10063):3060–73.
- Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. *Lancet*. 2012;379(9828):1835–46.
- Bonnarens F, Einhorn TA. Production of a standard closed fracture in laboratory animal bone. *J Orthop Research: Official Publication Orthop Res Soc*. 1984;2:97–101.
- Huang L, Harvie G, Feitelson JS, Gramatikoff K, Herold DA, Allen DL, Amunngama R, Hagler RA, Pisano MR, Zhang WW, Fang X. Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. *Proteomics* 5: 3314–3328, 2005.
- Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, Li K, Zhang G, Jin Z, He F, Hermjakob H, Zhu Y. iProX: an integrated proteome resource. *Nucleic Acids Res*. 2019;47(D1):D1211–7.
- Chen T, Ma J, Liu Y, Chen Z, Xiao N, Lu Y, Fu Y, Yang C, Li M, Wu S, Wang X, Li D, He F, Hermjakob H, Zhu Y. iProX in 2021: connecting proteomics data sharing with big data. *Nucleic Acids Res*. 2022;50(D1):D1522–7.
- Meng Z, Veenstra TD. Proteomic analysis of serum, plasma, and lymph for the identification of biomarkers. *Proteom Clin Appl*. 2007;1(8):747–57.
- Lind-Holm Mogensen F, Scafdi A, Poli A, Michelucci A. PARK7/DJ-1 in microglia: implications in Parkinson's disease and relevance as a therapeutic target. *J Neuroinflammation*. 2023;20(1):95.
- Rønning SB, Andersen PV, Pedersen ME, Hollung K. Primary bovine skeletal muscle cells enters apoptosis rapidly via the intrinsic pathway when available oxygen is removed. *PLoS ONE*. 2017;12(8):e0182928.
- Wenzel SE, Tyurina YY, Zhao J, St Croix CM, Dar HH, Mao G, Tyurin VA, Anthony-muthu TS, Kapralov AA, Amoscato AA, Mikulska-Ruminska K, Shrivastava IH, Kenny EM, Yang Q, Rosenbaum JC, Sparvero LJ, Emler DR, Wen X, Minami Y, Qu F, Watkins SC, Holman TR, VanDemark AP, Kellum JA, Bahar I, Bayir H, Kagan VE. PEBP1 warden ferroptosis by enabling lipoxygenase generation of lipid death signals. *Cell*. 2017;171(3):628–e64126.
- Wu M, Deng C, Lo TH, Chan KY, Li X, Wong CM. Peroxiredoxin, Senescence, and Cancer. *Cells*. 2022;11(11):1772.
- Vogel S, Bodenstern R, Chen Q, Feil S, Feil R, Rheinlaender J, Schäffer TE, Bohn E, Frick JS, Borst O, Münzer P, Walker B, Markel J, Csanyi G, Pagano PJ, Loughran P, Jessup ME, Watkins SC, Bullock GC, Sperry JL, Zuckerbraun BS, Billiar TR, Lotze MT, Gawaz M, Neal MD. Platelet-derived HMGB1 is a critical mediator of thrombosis. *J Clin Invest*. 2015;125(12):4638–54.
- Vulliamy P, Kornblith LZ, Kutcher ME, Cohen MJ, Brohi K, Neal MD. Alterations in platelet behavior after major trauma: adaptive or maladaptive? *Platelets*. 2021;32(3):295–304.
- Tweardy DJ, Khoshnevis MR, Yu B, Mastrangelo MA, Hardison EG, López JA. Essential role for platelets in organ injury and inflammation in resuscitated hemorrhagic shock. *Shock*. 2006;26(4):386–90.
- Kinross JM, Alkhamesi N, Barton RH, Silk DB, Yap IK, Darzi AW, Holmes E, Nicholson JK. Global metabolic phenotyping in an experimental laparotomy model of surgical trauma. *J Proteome Res*. 2011;10(1):277–87.
- D'Alessandro A, Moore HB, Moore EE, Wither M, Nemkov T, Gonzalez E, Slaughter A, Fragoso M, Hansen KC, Silliman CC, Banerjee A. Early hemorrhage triggers metabolic responses that build up during prolonged shock. *Am J Physiol Regul Integr Comp Physiol*. 2015;308(12):R1034–44.
- Peltz ED, D'Alessandro A, Moore EE, Chin T, Silliman CC, Sauaia A, Hansen KC, Banerjee A. Pathologic metabolism: an exploratory study of the plasma metabolome of critical injury. *J Trauma Acute Care Surg*. 2015;78(4):742–51.
- D'Alessandro A, Nemkov T, Moore HB, Moore EE, Wither M, Nydam T, Slaughter A, Silliman CC, Banerjee A, Hansen KC. Metabolomics of trauma-associated death: shared and fluid-specific features of human plasma vs lymph. *Blood Transfus*. 2016;14(2):185–94.
- Cohen MJ, Erickson CB, Lacroix IS, Debot M, Dzieciatkowska M, Schaid TR, Hallas MW, Thielen ON, Cralley AL, Banerjee A, Moore EE, Silliman CC, D'Alessandro A, Hansen KC. Trans-Omics analysis of post injury thromboinflammation identifies endotypes and trajectories in trauma patients. *bioRxiv [Preprint]*. 2023 Sep 9:2023.08.16.553446.
- Froese DS, Fowler B, Baumgartner MR. Vitamin B12, folate, and the methionine remethylation cycle-biochemistry, pathways, and regulation. *J Inher Metab Dis*. 2019;42(4):673–85.
- Calderón-Larrañaga A, Saadeh M, Hooshmand B, Refsum H, Smith AD, Marenconi A, Vetrano DL. Association of Homocysteine, Methionine, and MTHFR 677C>T polymorphism with rate of Cardiovascular Multimorbidity Development in older adults in Sweden. *JAMA Netw Open*. 2020;3(5):e205316.
- Yang M, Smith BC. Cysteine and methionine oxidation in thrombotic disorders. *Curr Opin Chem Biol*. 2023;76:102350.
- Tøndel BG, Morelli VM, Hansen JB, Braekkan SK. Risk factors and predictors for venous thromboembolism in people with ischemic stroke: a systematic review. *J Thromb Haemost*. 2022;20(10):2173–86.
- Liu P, Zhu W, Chen C, Yan B, Zhu L, Chen X, Peng C. The mechanisms of lysophosphatidylcholine in the development of diseases. *Life Sci*. 2020;247:117443.
- Foster R, Jung J, Farooq A, McClung C, Ripsch MS, Fitzgerald MP, White FA. Sciatic nerve injury induces functional pro-nociceptive chemokine receptors in bladder-associated primary afferent neurons in the rat. *Neuroscience*. 2011;183:230–7.
- Ryborg AK, Deleuran B, Søgaard H, Kragballe K. Intracutaneous injection of lysophosphatidylcholine induces skin inflammation and accumulation of leukocytes. *Acta Derm Venereol*. 2000 Jul-Aug;80(4):242–6.
- Morishita K, Aiboshi J, Kobayashi T, Mikami S, Yokoyama Y, Ogawa K, Yokota H, Otomo Y. Lipidomics analysis of mesenteric lymph after trauma and hemorrhagic shock. *J Trauma Acute Care Surg*. 2012;72(6):1541–7.
- Chiang JYL, Ferrell JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. *Am J Physiol Gastrointest Liver Physiol*. 2020;318(3):G554–73.
- Yin Y, Sun G, Li E, Kiselyov K, Sun D. ER stress and impaired autophagy flux in neuronal degeneration and brain injury. *Ageing Res Rev*. 2017;34:3–14.

46. Marinelli S, Vacca V, De Angelis F, Pieroni L, Orsini T, Parisi C, Soligo M, Protto V, Manni L, Guerrieri R, Pavone F. Innovative mouse model mimicking human-like features of spinal cord injury: efficacy of docosahexaenoic acid on acute and chronic phases. *Sci Rep.* 2019;9(1):8883.
47. Descorbeth M, Figueroa K, Serrano-Illán M, De León M. Protective effect of docosahexaenoic acid on lipotoxicity-mediated cell death in Schwann cells: implication of PI3K/AKT and mTORC2 pathways. *Brain Behav.* 2018;8(11):e011123.
48. Oliver JM, Jones MT, Kirk KM, Gable DA, Repshas JT, Johnson TA, Andréasson U, Norgren N, Blennow K, Zetterberg H. Effect of Docosahexaenoic Acid on a biomarker of Head Trauma in American Football. *Med Sci Sports Exerc.* 2016;48(6):974–82.
49. Kelly RS, Sordillo JE, Lasky-Su J, Dahlin A, Perng W, Rifas-Shiman SL, Weiss ST, Gold DR, Litorjua AA, Hivert MF, Oken E, Wu AC. Plasma metabolite profiles in children with current asthma. *Clin Exp Allergy.* 2018;48(10):1297–304.
50. Ferrell M, Wang Z, Anderson JT, Li XS, Witkowski M, DiDonato JA, Hilser JR, Hartiala JA, Haghikia A, Cajka T, Fiehn O, Sangwan N, Demuth I, König M, Steinhagen-Thiessen E, Landmesser U, Tang WHW, Allayee H, Hazen SL. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. *Nat Med.* 2024;30(2):424–34.
51. Zhou R, Huang Y, Tian C, Yang Y, Zhang Z, He K. Coptis chinensis and Berberine Ameliorate Chronic Ulcerative Colitis: an Integrated Microbiome-Metabolomics Study. *Am J Chin Med.* 2023;51(8):2195–220.
52. Rutkowski B, Slominska E, Szolkiewicz M, Smolenski RT, Striley C, Rutkowski P, Swierczynski J. N-methyl-2-pyridone-5-carboxamide: a novel uremic toxin? *Kidney Int Suppl.* 2003;(84):S19–21.
53. Mao X, Gu C, Ren M, Chen D, Yu B, He J, Yu J, Zheng P, Luo J, Luo Y, Wang J, Tian G, Yang Q. I-Isoleucine administration alleviates Rotavirus infection and Immune Response in the weaned piglet model. *Front Immunol.* 2018;9:1654.
54. Fehlbaum P, Rao M, Zasloff M, Anderson GM. An essential amino acid induces epithelial beta -defensin expression. *Proc Natl Acad Sci U S A.* 2000;97(23):12723–8.
55. Zhao J, Feng L, Liu Y, Jiang W, Wu P, Jiang J, Zhang Y, Zhou X. Effect of dietary isoleucine on the immunity, antioxidant status, tight junctions and microflora in the intestine of juvenile Jian carp (*Cyprinus carpio* var. Jian). *Fish Shellfish Immunol.* 2014;41(2):663–73.
56. Zhang S, Zeng X, Ren M, Mao X, Qiao S. Novel metabolic and physiological functions of branched chain amino acids: a review. *J Anim Sci Biotechnol.* 2017;8:10.
57. Aghazadeh Y, Zirkin BR, Papadopoulos V. Pharmacological regulation of the cholesterol transport machinery in steroidogenic cells of the testis. *Vitam Horm.* 2015;98:189–227.
58. Feklicheva I, Boks MP, de Kloet ER, Chipeeva N, Maslennikova E, Pashkov A, Korobova S, Komelkova M, Kuznetsova Y, Platkovski P, Mamonova M, Sidorenko O, Vasilenko T, Tseilikman O, Tseilikman V. Biomarkers in PTSD-susceptible and resistant veterans with war experience of more than ten years ago: FOCUS ON cortisol, thyroid hormones, testosterone and GABA. *J Psychiatr Res.* 2022;148:258–63.
59. Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. *J Endocrinol.* 2013;217(3):R25–45.
60. Bandeira L, Silva BC, Bilezikian JP. Male osteoporosis. *Arch Endocrinol Metab.* 2022;66(5):739–47.
61. Van Gent JM, Calvo RY, Zander AL, Olson EJ, Sise CB, Sise MJ, Shackford SR. Risk factors for deep vein thrombosis and pulmonary embolism after traumatic injury: a competing risks analysis. *J Trauma Acute Care Surg.* 2017;83(6):1154–60.
62. Brinker MR, O'Connor DP. The incidence of fractures and dislocations referred for orthopaedic services in a capitated population. *J Bone Joint Surg Am.* 2004;86(2):290–7.
63. Wang H, Zhang Y, Xiang Q, Wang X, Li C, Xiong H, Zhou Y. Epidemiology of traumatic spinal fractures: experience from medical university-affiliated hospitals in Chongqing, China, 2001–2010. *J Neurosurg Spine.* 2012;17(5):459–68.
64. Mills LA, Simpson AH. The relative incidence of fracture non-union in the Scottish population (5.17 million): a 5-year epidemiological study. *BMJ Open.* 2013;3(2):e002276.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.